Statement on the diagnosis and treatment of tobacco dependence in patients with cardiovascular diseases;Wspólne stanowisko dotycza̧ce rozpoznawania i leczenia zespołu uzależnienia od tytoniu u pacjentów z chorobami układu sercowo-naczyniowego

Kardiologia Polska

Volumn 69, Issue 1, 2011, Pages 96-100

  Zatoñski, Witold ^a   Jankowski, Piotr ^b   Banasiak, Waldemar ^c   Kawecka Jaszcz, Kalina ^d   Musiał, Jacek ^e   Narkiewicz, Krzysztof ^f   Opolski, Grzegorz ^g   Podolec, Piotr ^h   Torbicki, Adam ⁱ   Zembala, Marian ^j  

^a INSTITUTE OF ONCOLOGY   (Poland)

^b Zarza du Sekcji Epidemiologii I Prewencji Polskiego Towarzystwa Kardiologicznego   (Poland)

^c Polskiego Towarzystwa Kardiologicznego   (Poland)

^d Polskie Towarzystwo Nadci nienia T tniczego   (Poland)

^e Towarzystwa Internistów Polskich   (Poland)

^f Konsultant Krajowy w Dziedzinie Hipertensjologii   (Poland)

^g Konsultant Krajowy w Dziedzinie Kardiologii   (Poland)

^h Rady Redakcyjnej Polskiego Forum Profilaktyki Chorob Ukadu Krazenia   (Poland)

ⁱ Europejskiego Towarzystwa Kardiologicznego   (Poland)

^j Europejskiego Towarzystwa Chirurgii Serca i Naczyñ   (Poland)

more..

Author keywords

[No Author keywords available]

Indexed keywords

ARTICLE; CARDIOVASCULAR DISEASE; HUMAN; TOBACCO DEPENDENCE; METHODOLOGY; PATIENT ATTITUDE; POLAND; SMOKING; SMOKING CESSATION;

AMFEBUTAMONE; DOPAMINE UPTAKE INHIBITOR;

BUPROPION; CARDIOVASCULAR DISEASES; DOPAMINE UPTAKE INHIBITORS; HUMANS; PATIENT ACCEPTANCE OF HEALTH CARE; POLAND; SMOKING; SMOKING CESSATION; TOBACCO USE DISORDER;

EID: 79952210380     PISSN: 00229032     EISSN: 00229032     Source Type: Journal    
DOI: None     Document Type: Article

References (30)

1. Tonstad S, Johnston JA. Cardiovascular risks associated with smoking: a review for clinicians. Eur J Cardiovasc Prev Rehabil, 2006; 13: 507-514. (Pubitemid 44162150)
2. Powles JW, Zatonski W, Vander Hoorn S, Ezzati M. The contribution of leading diseases and risk factors to excess losses of healthy life in Eastern Europe: burden of disease study. BMC Public Health, 2005; 5: 116.
3. U.S. Department of Heath and Human Services. How Tobacco Smoke Causes Disease: The Biology and Behavioral Basis for Smoking-Attributable Disease. A Report of the Surgeon General. Atlanta, GA: U.S. Department of Health and Human Services, Centers for Disease Control and Prevention, National Center for Chronic Disease Prevention and Health Promotion, Office on Smoking and Health, 2010.
4. O'Donnell MJ, Xavier D, Liu L et al. Risk factors for ischaemic and intracerebral haemorrhagic stroke in 22 countries (the INTERSTROKE study): a case-control study. Lancet, 2010; 376: 112-123.
5. Rusanen M, Kivipelto M, Quesenberry ChP Jr, Zhou J, Whitmer RA. Heavy smoking in midlife and long-term risk of Alzheimer disease and vascular dementi. Arch Intern Med, 25 października 2010; www.archinternmed.com.
6. Szczech R, Hering D, Narkiewicz K. Smoking and cardiovascular risk: new mechanisms and further evidence for a 'guilty' verdict. J Hypertens, 2004; 22: 31-34.
7. Tonstad S. Smoking cessation: how to advise the patient. Heart, 2009; 95: 1635-1640.
8. European guidelines on cardiovascular disease prevention in clinical practice: full text. Fourth Joint Task Force of the European Society of Cardiology and other societies on cardiovascular disease prevention in clinical practice. Eur J Cardiovasc Prev Rehabil, 2007; 14 (suppl. 2): S1-S113.
9. Jankowski P, Kawecka-Jaszcz K, Surowiec S, Loster M, Wolfshaut R, Paja̧k A. Czȩstość palenia tytoniu wśród osób z choroba̧ niedokrwienna̧ serca w dekadzie 1997-2007. Wyniki Krakowskiego Programu Wtórnej Prewencji Choroby Niedokrwiennej Serca oraz polskich czȩści badań EUROASPIRE II i EUROASPIRE III. Zeszyty Naukowe Ochrony Zdrowia. Zdrowie Publiczne i Zarza̧dzanie, 2010; 7: 44-48.
10. Rigotti NA, Munafo MR, Stead LF. Smoking cessation interventions for hospitalized smokers: a systematic review. Arch Intern Med, 2008; 168: 1950-1960.
11. Mohiuddin SM, Mooss AN, Hunter CB, Grollmes TL, Cloutier DA, Hilleman DE. Intensive smoking cessation intervention reduces mortality in high-risk smokers with cardiovascular disease. Chest, 2007; 131: 446-452. (Pubitemid 46280405)
12. Zatoński W (przewodnicza̧cy). Konsensus dotycza̧cy rozpoznawania i leczenia zespołu uzależnienia od tytoniu. Med Prakt, 2006; 7 (wyd. specj.): 1-24.
13. Lancaster T, Stead LF. Individual behavioural counseling for smoking cessation. Cochrane Database System Rev, 2005; 2: DOI: 10.1002/14651858. CD001292.
14. Rice VH, Stead LF. Nursing interventions for smoking cessation. Cochrane Database System Rev, 2008; 1: DOI: 10.1002/14651858.CD001188.
15. Stead LF, Lancaster T. Physician advice for smoking cessation. Cochrane Database System Rev, 2008; 2: DOI:10.1002/14651858.CD000165.
16. Kawecka-Jaszcz K, Jankowski P, Podolec P et al. Polish forum for prevention guidelines on smoking. Kardiol Pol, 2008; 66: 125-126.
17. Clinical Practice Guideline Treating Tobacco Use and Dependence 2008 Update Panel. A clinical practice guideline for treating tobacco use and dependence: 2008 update. A U.S. Public Health Service Report. Am J Prev Med, 2008; 35: 158-176.
18. Piepoli MF, Corrà U, Benzer W et al. Secondary prevention through cardiac rehabilitation: from knowledge to implementation. A position paper from the Cardiac Rehabilitation Section of the European Association of Cardiovascular Prevention and Rehabilitation. Eur J Cardiovasc Prev Rehabil, 2010; 17: 1-17.
19. National Institute for Health and Clinical Evidence. NICE guidance on smoking cessation services. http://www.nice.org.uk/ /guidance/PH10.
20. Stead LF, Perera R, Bullen C, Mant D, Lancaster T. Nicotine replacement therapy for smoking cessation. Cochrane Database System Rev, 2008; 1: DOI: 10.1002/14651858.CD000146.
21. Hughes JR, Stead LF, Lancaster T. Antidepressants for smoking cessation. Cochrane Database System Rev, 2007; 1: DOI: 10.1002/14651858.CD000031.
22. Tonstad S, Farsang C, Klaene G et al. Bupropion SR for smoking cessation in smokers with cardiovascular disease: a multicentre, randomised study. Eur Heart J, 2003; 24: 946-955. (Pubitemid 36559988)
23. Parsons AC, Shraim M, Inglis J, Aveyard P, Hajek P. Interventions for preventing weight gain after smoking cessation. Cochrane Database Syst Rev, 2009; 1: DOI: 10.1002/14651858.CD006219.
24. Cahill K, Stead LF, Lancaster T. Nicotine receptor partial agonists for smoking cessation. Cochrane Database System Rev, 2010; 12: DOI: 10.1002/14651858.CD006103.
25. Rigotti NA, Pipe AL, Benowitz NL et al. Efficacy and safety of varenicline for smoking cessation in patients with cardiovascular disease: a randomized trial. Circulation, 2010; 121: 221-229.
26. Tonstad S, Davies S, Flammer M, Russ C, Hughes J. Psychiatric adverse events in randomized, double-blind, placebo-controlled clinical trials of varenicline: a pooled analysis. Drug Saf, 2010; 33: 289-301.
27. Coe JW, Brooks PR, Vetelino MG et al. Varenicline: an alpha4beta2 nicotinic receptor partial agonist for smoking cessation. J Med Chem, 2005; 48: 3474-3477. (Pubitemid 40664098)
28. Tutka P, Mróz K, Zatoński W. Cytyzyna - renesans znanego alkaloidu. Aspekty farmakologiczne zastosowania w leczeniu uzależnienia od nikotyny. Farm Psych Neurol, 2006; 1: 33-39.
29. Zato?ski W, Cedzy?ska M, Tutka P, West R. An uncontrolled trial of cytisine (Tabex) for smoking cessation. Tob Control, 2006; 15: 481-484. (Pubitemid 44935576)
30. Guidelines on myocardial revascularization The Task Force on Myocardial Revascularization of the European Society of Cardiology (ESC) and the European Association for Cardio-Thoracic Surgery (EACTS). Eur Heart J, 2010; 31: 2501-2555.